NO313457B1 - Hydroksamsyrederivater - Google Patents

Hydroksamsyrederivater Download PDF

Info

Publication number: NO313457B1
Authority: NO; Norway
Prior art keywords: methyl; hydroxy; methylamide; diamide; hydroxyl
Prior art date: 1996-10-02

Application number

NO19991559A

Other languages

English (en)

Norwegian (no)

Other versions

NO991559L (no

NO991559D0 (no

Inventor

Georg Kottirsch

Ulf Neumann

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-02

Filing date

1999-03-30

Publication date

2002-10-07

1996-10-02 Priority claimed from GBGB9620572.9A external-priority patent/GB9620572D0/en

1997-04-02 Priority claimed from GBGB9706667.4A external-priority patent/GB9706667D0/en

1999-03-30 Application filed by Novartis Ag filed Critical Novartis Ag

1999-03-30 Publication of NO991559L publication Critical patent/NO991559L/no

1999-03-30 Publication of NO991559D0 publication Critical patent/NO991559D0/no

2002-10-07 Publication of NO313457B1 publication Critical patent/NO313457B1/no

Links

NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title description 9
239000002253 acid Substances 0.000 title description 8
150000001875 compounds Chemical class 0.000 claims description 61
238000011282 treatment Methods 0.000 claims description 13
125000000217 alkyl group Chemical group 0.000 claims description 10
238000000034 method Methods 0.000 claims description 10
-1 phenyl-C1.4-alkyl Chemical group 0.000 claims description 10
150000003839 salts Chemical group 0.000 claims description 10
230000001363 autoimmune Effects 0.000 claims description 6
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
208000023275 Autoimmune disease Diseases 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
125000003545 alkoxy group Chemical group 0.000 claims description 3
208000027866 inflammatory disease Diseases 0.000 claims description 3
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
125000001624 naphthyl group Chemical group 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 23
239000000047 product Substances 0.000 description 14
102000003390 tumor necrosis factor Human genes 0.000 description 13
108060005980 Collagenase Proteins 0.000 description 10
102000029816 Collagenase Human genes 0.000 description 10
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 10
229960002424 collagenase Drugs 0.000 description 10
239000000243 solution Substances 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
210000004027 cell Anatomy 0.000 description 6
239000000203 mixture Substances 0.000 description 6
RMXLHIUHKIVPAB-OWOJBTEDSA-N (e)-1,4-dibromobut-2-ene Chemical compound BrC\C=C\CBr RMXLHIUHKIVPAB-OWOJBTEDSA-N 0.000 description 5
GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 5
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
239000012074 organic phase Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
230000002265 prevention Effects 0.000 description 5
239000000741 silica gel Substances 0.000 description 5
229910002027 silica gel Inorganic materials 0.000 description 5
SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 4
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
206010003246 arthritis Diseases 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
230000004968 inflammatory condition Effects 0.000 description 4
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 3
102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
241000700159 Rattus Species 0.000 description 3
101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 3
101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 3
206010040070 Septic Shock Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
231100000433 cytotoxic Toxicity 0.000 description 3
230000001472 cytotoxic effect Effects 0.000 description 3
230000003013 cytotoxicity Effects 0.000 description 3
231100000135 cytotoxicity Toxicity 0.000 description 3
150000001470 diamides Chemical class 0.000 description 3
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
206010006895 Cachexia Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
201000001263 Psoriatic Arthritis Diseases 0.000 description 2
208000036824 Psoriatic arthropathy Diseases 0.000 description 2
108700012920 TNF Proteins 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000005984 hydrogenation reaction Methods 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
FGKJLKRYENPLQH-UHFFFAOYSA-N isocaproic acid Chemical compound CC(C)CCC(O)=O FGKJLKRYENPLQH-UHFFFAOYSA-N 0.000 description 2
239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 2
229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000036303 septic shock Effects 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
108091007196 stromelysin Proteins 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000000758 substrate Substances 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
230000006433 tumor necrosis factor production Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
CUZKCNWZBXLAJX-UHFFFAOYSA-N 2-phenylmethoxyethanol Chemical compound OCCOCC1=CC=CC=C1 CUZKCNWZBXLAJX-UHFFFAOYSA-N 0.000 description 1
YPKWBRDPISTIQN-UHFFFAOYSA-N 3-imino-4-oxoheptanedioic acid Chemical compound OC(=O)CCC(=O)C(=N)CC(O)=O YPKWBRDPISTIQN-UHFFFAOYSA-N 0.000 description 1
RFNSXSSACWHHMN-UHFFFAOYSA-N 4-benzyl-1,2-dihydrotriazol-5-one Chemical compound N1N=NC(CC=2C=CC=CC=2)=C1O RFNSXSSACWHHMN-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
208000003556 Dry Eye Syndromes Diseases 0.000 description 1
206010013774 Dry eye Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
206010060742 Endocrine ophthalmopathy Diseases 0.000 description 1
206010014824 Endotoxic shock Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
108010026132 Gelatinases Proteins 0.000 description 1
102000013382 Gelatinases Human genes 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 1
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
208000004883 Lipoid Nephrosis Diseases 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010064996 Ulcerative keratitis Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
208000010399 Wasting Syndrome Diseases 0.000 description 1
208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
208000002205 allergic conjunctivitis Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
238000003556 assay Methods 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical class OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000002442 collagenase inhibitor Substances 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
229940043279 diisopropylamine Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000035622 drinking Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
208000007565 gingivitis Diseases 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
230000002969 morbid Effects 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000004768 organ dysfunction Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
150000003891 oxalate salts Chemical class 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
201000001245 periodontitis Diseases 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
206010035653 pneumoconiosis Diseases 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
BIXNGBXQRRXPLM-UHFFFAOYSA-K ruthenium(3+);trichloride;hydrate Chemical compound O.Cl[Ru](Cl)Cl BIXNGBXQRRXPLM-UHFFFAOYSA-K 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000002884 skin cream Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
208000018464 vernal keratoconjunctivitis Diseases 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyridine Compounds (AREA)

NO19991559A 1996-10-02 1999-03-30 Hydroksamsyrederivater NO313457B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9620572.9A GB9620572D0 (en)	1996-10-02	1996-10-02	Organic compounds
GBGB9706667.4A GB9706667D0 (en)	1997-04-02	1997-04-02	Organic compounds
PCT/EP1997/005376 WO1998014424A1 (en)	1996-10-02	1997-09-30	Hydroxamic acid derivatives

Publications (3)

Publication Number	Publication Date
NO991559L NO991559L (no)	1999-03-30
NO991559D0 NO991559D0 (no)	1999-03-30
NO313457B1 true NO313457B1 (no)	2002-10-07

Family

ID=26310147

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19991559A NO313457B1 (no)	1996-10-02	1999-03-30	Hydroksamsyrederivater

Country Status (28)

Country	Link
EP (1)	EP0929517B1 (de)
JP (1)	JP3444898B2 (de)
KR (1)	KR20000048811A (de)
CN (1)	CN1101807C (de)
AR (1)	AR009103A1 (de)
AT (1)	ATE219050T1 (de)
AU (1)	AU726065B2 (de)
BR (1)	BR9712255A (de)
CA (1)	CA2267415A1 (de)
CO (1)	CO4900034A1 (de)
CZ (1)	CZ113999A3 (de)
DE (1)	DE69713354T2 (de)
DK (1)	DK0929517T3 (de)
ES (1)	ES2178759T3 (de)
HU (1)	HUP9903892A3 (de)
ID (1)	ID22212A (de)
IL (1)	IL129166A0 (de)
MY (1)	MY127926A (de)
NO (1)	NO313457B1 (de)
NZ (1)	NZ334908A (de)
PE (1)	PE2099A1 (de)
PL (1)	PL188518B1 (de)
PT (1)	PT929517E (de)
RU (1)	RU2196131C2 (de)
SI (1)	SI0929517T1 (de)
SK (1)	SK43099A3 (de)
TR (1)	TR199900725T2 (de)
WO (1)	WO1998014424A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003294917A1 (en) *	2002-12-20	2004-07-14	Novartis Ag	Device and method for delivering mmp inhibitors
CA2534352A1 (en)	2003-08-08	2005-02-17	Arriva Pharmaceuticals, Inc.	Methods of protein production in yeast
CA2559062A1 (en)	2004-03-09	2005-09-22	Arriva Pharmaceuticals, Inc.	Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
CN1951912B (zh) *	2005-10-18	2010-05-05	上海五洲药业股份有限公司	手性脂环烃异羟肟酸衍生物的制备方法
GB0818907D0 (en) *	2008-10-15	2008-11-19	Isis Innovation	Histone lysine demethylase inhibitors
KR102410199B1 (ko) *	2016-04-18	2022-06-17	프라운호퍼-게젤샤프트 츄어 푀르더룽 데어 안게반텐 포르슝에.파우.	새로운 메프린 알파 및 베타 저해제

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK77487A (da) *	1986-03-11	1987-09-12	Hoffmann La Roche	Hydroxylaminderivater
GB9223904D0 (en) *	1992-11-13	1993-01-06	British Bio Technology	Inhibition of cytokine production
DE69502378T2 (de) *	1994-01-20	1998-10-01	British Biotech Pharm	Metalloproteinaseinhibitoren
FI962905A0 (fi) *	1994-01-22	1996-07-19	British Biotech Pharm	Metalloproteinaasi-inhibiittoreita
GB9416897D0 (en) *	1994-08-20	1994-10-12	British Biotech Pharm	Metalloproteinase inhibitors
GB9423914D0 (en) *	1994-11-26	1995-01-11	British Biotech Pharm	Polyether derivatives as metalloproteinase inhibitors

1997
- 1997-09-30 ID IDW990143D patent/ID22212A/id unknown
- 1997-09-30 CN CN97198511A patent/CN1101807C/zh not_active Expired - Fee Related
- 1997-09-30 BR BR9712255A patent/BR9712255A/pt not_active Application Discontinuation
- 1997-09-30 EP EP97909339A patent/EP0929517B1/de not_active Expired - Lifetime
- 1997-09-30 DE DE69713354T patent/DE69713354T2/de not_active Expired - Lifetime
- 1997-09-30 PE PE1997000874A patent/PE2099A1/es not_active Application Discontinuation
- 1997-09-30 CZ CZ991139A patent/CZ113999A3/cs unknown
- 1997-09-30 JP JP51623698A patent/JP3444898B2/ja not_active Expired - Fee Related
- 1997-09-30 SI SI9730357T patent/SI0929517T1/xx unknown
- 1997-09-30 ES ES97909339T patent/ES2178759T3/es not_active Expired - Lifetime
- 1997-09-30 KR KR1019990702806A patent/KR20000048811A/ko not_active Ceased
- 1997-09-30 AT AT97909339T patent/ATE219050T1/de not_active IP Right Cessation
- 1997-09-30 TR TR1999/00725T patent/TR199900725T2/xx unknown
- 1997-09-30 PL PL97332477A patent/PL188518B1/pl not_active IP Right Cessation
- 1997-09-30 NZ NZ334908A patent/NZ334908A/xx unknown
- 1997-09-30 CA CA002267415A patent/CA2267415A1/en not_active Abandoned
- 1997-09-30 AR ARP970104491A patent/AR009103A1/es unknown
- 1997-09-30 RU RU99108792/04A patent/RU2196131C2/ru not_active IP Right Cessation
- 1997-09-30 WO PCT/EP1997/005376 patent/WO1998014424A1/en not_active Ceased
- 1997-09-30 IL IL12916697A patent/IL129166A0/xx not_active IP Right Cessation
- 1997-09-30 AU AU47068/97A patent/AU726065B2/en not_active Ceased
- 1997-09-30 DK DK97909339T patent/DK0929517T3/da active
- 1997-09-30 HU HU9903892A patent/HUP9903892A3/hu unknown
- 1997-09-30 PT PT97909339T patent/PT929517E/pt unknown
- 1997-09-30 SK SK430-99A patent/SK43099A3/sk unknown
- 1997-10-01 CO CO97057298A patent/CO4900034A1/es unknown
- 1997-10-01 MY MYPI97004587A patent/MY127926A/en unknown
1999
- 1999-03-30 NO NO19991559A patent/NO313457B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
JP3444898B2 (ja)	2003-09-08
EP0929517B1 (de)	2002-06-12
JP2000508338A (ja)	2000-07-04
KR20000048811A (ko)	2000-07-25
IL129166A0 (en)	2000-02-17
CA2267415A1 (en)	1998-04-09
DE69713354D1 (de)	2002-07-18
CZ113999A3 (cs)	1999-06-16
PL332477A1 (en)	1999-09-13
NO991559L (no)	1999-03-30
DE69713354T2 (de)	2002-12-05
NO991559D0 (no)	1999-03-30
AR009103A1 (es)	2000-03-08
CO4900034A1 (es)	2000-03-27
RU2196131C2 (ru)	2003-01-10
HUP9903892A3 (en)	2000-04-28
NZ334908A (en)	2000-10-27
DK0929517T3 (da)	2002-10-07
ID22212A (id)	1999-09-16
PL188518B1 (pl)	2005-02-28
CN1232447A (zh)	1999-10-20
PE2099A1 (es)	1999-02-08
ES2178759T3 (es)	2003-01-01
ATE219050T1 (de)	2002-06-15
HUP9903892A2 (hu)	2000-03-28
AU726065B2 (en)	2000-10-26
WO1998014424A1 (en)	1998-04-09
HK1021637A1 (en)	2000-06-23
SK43099A3 (en)	1999-08-06
EP0929517A1 (de)	1999-07-21
PT929517E (pt)	2002-10-31
BR9712255A (pt)	1999-08-24
TR199900725T2 (xx)	1999-07-21
AU4706897A (en)	1998-04-24
SI0929517T1 (en)	2002-10-31
CN1101807C (zh)	2003-02-19
MY127926A (en)	2006-12-29

Legal Events

Date	Code	Title	Description
2010-04-26	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
RU2485095C2 (ru)	2013-06-20	Кристаллическое основание миноциклина и способы его получения
EP1019374B1 (de)	2003-01-02	Polymorphe von donepezyl-hydrochlorid und verfahren zur herstellung
WO1997046526A1 (en)	1997-12-11	Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
JP3066083B2 (ja)	2000-07-17	１―ベンジル―４―（（５，６―ジメトキシ―１―インダノン）―２―イル）メチルピペリジンを調製する方法及びそのための中間物質
NO180482B (no)	1997-01-20	Analogifremgangsmåte for fremstilling av terapeutisk aktive hydroksamsyrer og N-hydroksyurinstoffer
NO313457B1 (no)	2002-10-07	Hydroksamsyrederivater
US6500983B2 (en)	2002-12-31	Hydroxamic acid derivatives
EP1497273B1 (de)	2010-06-09	Hydroxamsäurederivate
MC1960A1 (fr)	1989-06-30	Derives d'acide hydrocinnamique
HK1021637B (en)	2003-05-02	Hydroxamic acid derivatives
EP1383761B1 (de)	2011-03-02	Phenyl- und pyridyl-piperidine mit tnf-wirkung
KR20180124428A (ko)	2018-11-21	결정형 사쿠비트릴 헤미나트륨염, 이의 제조방법 및 이를 포함하는 약학 조성물
AU6995994A (en)	1995-01-17	N-substituted azaheterocyclic carboxylic acids and esters thereof
EP1384708A1 (de)	2004-01-28	Verfahren zur Herstellung der Form I von Nolomirol Hydrochlorid
JPH08511782A (ja)	1996-12-10	Ｎ−置換アザ複素環式カルボン酸類とそのエステル類
JPH07100687B2 (ja)	1995-11-01	新規なｎ−ヒドロキシ尿素化合物および組成物
EP1178962A1 (de)	2002-02-13	Verfahren zur herstellung von paroxetinacetat und analoge davon